✦ LIBER ✦

Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II study

✍ Scribed by Martee L. Hensley; John A. Blessing; Koen DeGeest; Ovadia Abulafia; Peter G. Rose; Howard D. Homesley

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Fixed-dose rate gemcitabine plus docetax

✍ Martee L. Hensley; John A. Blessing; Robert Mannel; Peter G. Rose 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 182 KB

Phase II trial of gemcitabine as second-

✍ Katherine Y Look; Alan Sandler; John A Blessing; Joseph A Lucci III; Peter G Ros 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 97 KB

A randomized phase III trial of gemcitab

✍ Hensley, M.L.; Miller, A.; O'Malley, D.M.; Mannel, R.S.; Behbakht, K.; Bakkum-Ga 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 110 KB

A phase II evaluation of weekly gemcitab

✍ Brigitte E. Miller; John A. Blessing; Frederick B. Stehman; Mark S. Shahin; S. D 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 239 KB

Phase I dose-escalation study and popula

✍ Leijen, Suzanne; Veltkamp, Stephan A.; Huitema, Alwin D.R.; van Werkhoven, E.; B 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 306 KB

A Phase II Trial of Prolonged Oral Etopo

✍ Peter G. Rose; John A. Blessing; George S. Lewandowski; William T. Creasman; Ken 📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 68 KB